Studying microRNAs and kidney damage in chronic kidney disease

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for three groups of adults: healthy people with normal blood pressure, people with high blood pressure, and people with chronic kidney disease stage 3-5.

Age

18 to 69 years

Sex

All sexes can join

Disease stage

Healthy adults with normal blood pressure (eGFR CKD-EPI >90 mL/min/1.73 m2, BP <140/90 mmHg); adults with high blood pressure (eGFR CKD-EPI >90 mL/min/1.73 m2, BP >140/90 mmHg); or chronic kidney disease stage 3-5 (eGFR CKD-EPI < 60 mL/min/1.73 m2)

Main reasons for not taking part

• Heart or blood vessel diseases other than high blood pressure
• Diabetes
• Cerebrovascular diseases
• Peripheral artery disease

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 18 and 69 years old?YesNo

What the trial wants to find out

Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys promotes renal vascular remodeling and increases preglomerular resistance. These are key elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy. Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs (miRNAs) are regulators of gene expression and play a role in the progression of renal ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage under conditions of oxidative and ER stress remains understudied.

The 3 groups in the trial

• Chronic kidney disease group

  Patients with stage 3-5 CKD (eGFR CKD-EPI \<60 mL/min/1.73 m2)

• Healthy controls

  Healthy normotensive patients (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \<140/90 mmHg)

• Hypertensive Group

  Hypertensive patients without CKD (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \>140/90 mmHg)